Intervention1: Semaglutide Injection 15 mg/3 mL (5 mg/mL): Test product will be administered once weekly at any time of day, with or without meals for 24 weeks. Injection will be administered subcutan
Sponsors
Zydus Lifesciences Limited
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complicationsHealth Condition 1: E669- Obesity, unspecified
Health Condition 2: E669- Obesity, unspecified
Phase 3
A clinical study to evaluate the efficacy and safety of Semaglutide Injection in patients with weight management.
Active, not recruitingCTRI/2025/03/082620
Target: 282Updated: 2025-12-08
A clinical study to evaluate the efficacy and safety of Semaglutide Injection in patients with type 2 diabetes mellitus.
Active, not recruitingCTRI/2025/03/082615
Target: 314Updated: 2025-11-17